Comparison of previous reports of intravitreal bevacizumab for myopic choroidal neovascularisation and the present study
| Author | Year | No of eyes (patients) | Mean age | Base best-corrected visual acuity (logMAR) | Duration of symptom before treatment | Ethnicity | Previous treatments | Treatment for outcome measurement | Follow-up (years) | No of treatments | Visual outcome | Chorioretinal atrophy development (area) | Comparison between PDT and IVB |
| Ikuno12 | 2009 | 63 (63) | 58.4±13.6 | 0.57±0.43 | Within 2 years (mean 4.0 months) | Japanese | TA (7.9%) | IVB (1 mg) | 1 | 2.4±1.4 | Improved>3 lines (40%) unchanged (56%) Worsened>3 lines (5%) | NA | No |
| Gharbiya13 | 2009 | 20 (20) | 53(33 to 77) | 0.50±0.24 | NA | Italy | PDT (10%) | IVB (1.25 mg) | 1 | 4.0±1.5 | Improved>3 lines (70%) Improved>2 lines (90%) | NA | No |
| Wu and Chen14 | 2009 | 8 (8) | 41.5±13.0 | 0.6 | NA | Chinese | NA | IVB (2.5 mg) | 1 | 1.4±0.5 | Mean Improved 5 lines | NA | No |
| Chan et al15 | 2009 | 29 (29) | 48.9±15.3 | 0.62±0.26 | Mean 1.9 months | Chinese | PDT (44.8%) | IVB (1.25 mg) | 1 | 3.1±0.4 | Improved>2 lines (72%) | NA | No |
| Ruiz-Monero16 | 2009 | 29 (29) | 50±15 | 0.55±0.25 | NA | (Spain) | PDT (46%) PDT+TA (3.6%) | IVB (1.25 mg) | 1 | 1.2±0.4 | Improved>2 lines (37%) Worsened>2 lines (11%) | NA | No |
| Hayashi17 | 2008 | 36 (35) | 55.1±14.3 | 0.58±0.42 | Within 6 months | Japanese | TA (19%) | PDT | 1 | 1.4±0.8 | Improved>3 lines (20%) Improved>2 lines (27%) | 50% (1.14±1.87 mm2) | Yes |
| 43 (43) | 57.5±12.3 | 0.60±0.28 | Within 6 months | Japanese | TA (7.9%) PDT (20.9%) PDT+TA (2.3%) | IVB (1.25 mg) | 1 | 1.6±0.7 | Improved>3 line< (42%) Improved>2 lines (49%) | 15.4% (0.33±0.86 mm2) | Yes | ||
| Baba et al* | 2009 | 12 (12) | 62.4±7.5 | 0.77±0.25 | Within 6 months (mean 4.1 months) | Japanese | None | PDT | 1 | 1.3±0.5 | Improved>3 lines (8%) Improved>2 lines (17%) Worsened>3 lines (17%) | 83% (1.5±1.0 DR) | Yes |
| 2 | 1.3±0.5 | Improved>3 lines (8%) Improved>2 lines (25%) Worsened>3 lines (17%) | 100% (2.0±1.4 DR) | Yes | |||||||||
| 12 (12) | 62.8±8.0 | 0.75±0.25 | Within 6 months (mean 3.7 months) | Japanese | None | IVB (1.25 mg) | 1 | 1.5±0.8 | Improved>3 lines (42%) Improved>2 lines (58%) Worsened>3 lines (0%) | 42% (0.5±0.4 DR) | Yes | ||
| 2 | 1.6±0.8 | Improved>3 lines (42%) Improved>2 lines (42%) Worsened>3 lines (0%) | 50% (0.6±0.5 DR) | Yes |
↵* The current study.
DR, disc ratio; IVB, intravitreal bevacizumab; PDT, photodynamic therapy; TA, triam cinolone acetonide injection.